Based on the key indicators related to Kiniksa Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Kiniksa Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At present, Kiniksa Pharmaceuticals' Total Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Stockholder Equity is expected to grow to about 460.4 M, whereas Total Assets are forecasted to decline to about 345.8 M. Key indicators impacting Kiniksa Pharmaceuticals' financial strength include:
The financial analysis of Kiniksa Pharmaceuticals is a critical element in measuring its lifeblood. Investors should not minimize Kiniksa Pharmaceuticals' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Please note, the presentation of Kiniksa Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kiniksa Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Kiniksa Pharmaceuticals' management manipulating its earnings.
Kiniksa Pharmaceuticals Stock Summary
Kiniksa Pharmaceuticals competes with Nuvalent, Ventyx Biosciences, Arcellx, Cullinan Oncology, and Day One. Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda. Kiniksa Pharmaceuticals is traded on NASDAQ Exchange in the United States.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Kiniksa Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Kiniksa Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kiniksa Pharmaceuticals competition to find correlations between indicators driving Kiniksa Pharmaceuticals's intrinsic value. More Info.
Kiniksa Pharmaceuticals is rated second overall in return on equity category among its peers. It also is rated second overall in return on asset category among its peers . At present, Kiniksa Pharmaceuticals' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Kiniksa Pharmaceuticals' earnings, one of the primary drivers of an investment's value.
Kiniksa Pharmaceuticals Systematic Risk
Kiniksa Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Kiniksa Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Kiniksa Pharmaceuticals correlated with the market. If Beta is less than 0 Kiniksa Pharmaceuticals generally moves in the opposite direction as compared to the market. If Kiniksa Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Kiniksa Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Kiniksa Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Kiniksa Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Kiniksa Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Kiniksa Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Kiniksa Pharmaceuticals growth as a starting point in their analysis.
Price Earnings To Growth Ratio
0.0859
At present, Kiniksa Pharmaceuticals' Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting.
Kiniksa Pharmaceuticals March 24, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Kiniksa Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Kiniksa Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Kiniksa Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Kiniksa Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Kiniksa Pharmaceuticals's daily price indicators and compare them against related drivers.
When running Kiniksa Pharmaceuticals' price analysis, check to measure Kiniksa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiniksa Pharmaceuticals is operating at the current time. Most of Kiniksa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiniksa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiniksa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiniksa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.